Home > Subjects > Chemistry > In Silico Selection in Relation to Aptamer, Based on Computational Docking

In Silico Selection in Relation to Aptamer, Based on Computational Docking

A Summary Analysis of In Silico Selection in relation to Aptamer, Based on Computational Docking

An important aspect of this topic ‘In Silico Selection in relation to Aptamer, Based on Computational Docking’ is the use of Aptamers. These are synthetic nucleic acid molecules that In Silico Selection in relation to Aptamer, Based on Computational Dockinghave the capability to bind any biological targets based on the quality of their three-dimensional and sequence structure. The selection of Aptamers is based on the use of Systematic Evolution of Ligands by EXponential enrichment, generally known as SELEX, this could be referred to as a method that employ Aptamer-target binding attractive force. (Caroli et al., 2015) In addition to this, the SELEX technique can be used with many other procedures, such as high-throughput sequencing (HT-SELEX) which in turn develops billions of random sequences that are able of binding together various epitopes on particular targets. (Caroli et al., 2015) Emphatically, Aptamers are usually in replacement of conventional antibodies since they are chemical-antibodies, as stated above, they are obtained from SELEX technology which involves multi-round choices and improvement. (Weigel & Dowsett, 2010)

Moreover, the human estrogen receptor, scientifically known as α (ERα) is also a 66 kDa ligand inducible transcription component that refers to a major mediator of 17β estradiol stimulator proliferation, distinction, and evolution of uterine and breast tissues. It is a very important biomarker which relates in the utilization in any breast cancer issues, diagnosis, and treatment. (Ali & Coombes, 2000) The effectiveness of the presence of ERα in close to two-thirds of any level of tumors and their consequent treatment relating to infantile fixation with hormonal therapy have developed ERα as an important and useful target for medical purposes. (Lippman & Alegra, 1980) In addition, the detection of any modified demonstration of ERα in cancer relating to the breast or any related diseases can be acted upon through with the use of ERα antibodies. Nevertheless, this antibody is based on applications regularly fraught with large complexity and cost of production, cross-reactivity, batch to batch variability, short shelf life, and contamination. (GomezFernandez et al., 2010)

Related Posts

Leave a Comment

eleven + 8 =